重组甘精胰岛素联合阿卡波糖对新诊断的2型糖尿病患者β细胞功能改善的自身对照研究
|
摘要
目的研究重组甘精胰岛素+阿卡波糖运用于新诊断的2型糖尿病患者中的价值及对β细胞功能的影响。方法选择2015年7月～2018年5月我院新诊断的2型糖尿病患者103例作为研究对象,给予重组甘精胰岛素+阿卡波糖进行治疗,观察治疗结果及治疗前后β细胞功能改善情况。结果治疗后治疗达标99例(96.12%),其余4例治疗未达标(3.88%),治疗达标的平均甘精胰岛素使用量为(24.36±1.05)U/d,达标时间(8.14±2.60)d,随访中发现低血糖发生率为2.91%(3/103);治疗前后患者的BMI、TC水平相比无差异(P>0.05),治疗后FBG、2hPG、糖化血红蛋白及TG水平均低于治疗前(P<0.05);治疗后患者的HOMA-β、HOMA-IR、AUC_(0-10)及AIR_(1-3)水平均优于治疗前(P<0.05);不良反应发生率为8.74%。结论重组甘精胰岛素+阿卡波糖运用于新诊断的2型糖尿病中效果明显,能够有效降低血糖水平,改善β细胞功能,控制病情,治疗后不良反应较少,安全性高,为预后提供保障。
Objective To study the value of recombinant insulin glargine +acarbose in patients with newly diagnosed type 2 diabetes and its effect on β-cell function. Methods A total of 103 patients with type 2 diabetes mellitus who were newly diagnosed in our hospital from July 2015 to May 2018 were enrolled in this study. The recombinant insulin glargine+acarbose were given for treatment. The treatment results and the improvement of β-cell function before and after treatment were observed. Results After treatment, 99 patients(96.12%) achieved the treatment goal, and the remaining 4 patients did not meet the standard(3.88%). The average dose of insulin glargine used in the effective treatment was(24.36±1.05) U/d, and the time to meet the standard was(8.14±2.60)d. The incidence of hypoglycemia was 2.91%(3/103) during follow-up. There was no difference in BMI and TC levels before and after treatment(P>0.05). The FBG, 2 hPG, glycosylated hemoglobin and TG levels after treatment were lower than those before treatment(P<0.05). The levels of HOMA-β, HOMA-IR, AUC_(0-10) and AIR_(1-3) after treatment were better than those before treatment(P<0.05). The incidence of adverse reactions was 8.74%. Conclusion Recombinant insulin glargine +acarbose is effective in newly diagnosed type 2 diabetes, which can effectively lower blood sugar level, improve β cell function, control the disease,have fewer adverse reactions after treatment, and have high safety, which provides insurance for prognosis.
Objective To study the value of recombinant insulin glargine +acarbose in patients with newly diagnosed type 2 diabetes and its effect on β-cell function. Methods A total of 103 patients with type 2 diabetes mellitus who were newly diagnosed in our hospital from July 2015 to May 2018 were enrolled in this study. The recombinant insulin glargine+acarbose were given for treatment. The treatment results and the improvement of β-cell function before and after treatment were observed. Results After treatment, 99 patients(96.12%) achieved the treatment goal, and the remaining 4 patients did not meet the standard(3.88%). The average dose of insulin glargine used in the effective treatment was(24.36±1.05) U/d, and the time to meet the standard was(8.14±2.60)d. The incidence of hypoglycemia was 2.91%(3/103) during follow-up. There was no difference in BMI and TC levels before and after treatment(P>0.05). The FBG, 2 hPG, glycosylated hemoglobin and TG levels after treatment were lower than those before treatment(P<0.05). The levels of HOMA-β, HOMA-IR, AUC_(0-10) and AIR_(1-3) after treatment were better than those before treatment(P<0.05). The incidence of adverse reactions was 8.74%. Conclusion Recombinant insulin glargine +acarbose is effective in newly diagnosed type 2 diabetes, which can effectively lower blood sugar level, improve β cell function, control the disease,have fewer adverse reactions after treatment, and have high safety, which provides insurance for prognosis.
引文
[1]黄建丽.国产重组甘精胰岛素注射液与来得时治疗糖尿病的效果和安全性比较[J].河南医学研究,2017,26(17):3156-3157.
[2]贾海英,李冬梅.社区门诊新诊断严重高血糖2型糖尿病患者起始基础胰岛素与基础胰岛素联合阿卡波糖治疗的对照研究[J].中国医刊,2018,53(1):41-44.
[3]宋玉香.国产重组甘精胰岛素注射液和来得时治疗糖尿病的安全性对比分析[J].中国实用医药,2016,11(8):150-151.
[4]钱荣立.糖尿病临床指南[M].北京:北京医科大学出版社,2000:210-213.
[5]房彦平,祝小林,李锦,等.阿卡波糖与二甲双胍对我国新发2型糖尿病的疗效及对胰岛功能的影响[J].中国医药科学,2017,7(19):65-67,108.
[6]魏滋鸿,李薇,武卫党,等.新型国产重组甘精胰岛素对1型糖尿病模型大鼠的降糖作用研究[J].药物评价研究,2018,41(8):1446-1449.
[7]樊实真,杨俊朋,张春玲,等.胰岛素促泌剂与阿卡波糖治疗新诊断2型糖尿病的疗效及对胰升血糖素样肽-1的调节作用[J].中国糖尿病杂志,2016,24(4):348-351.
[8]李春花,李可心,张英,等.重组甘精胰岛素联合格列美脲治疗糖尿病疗效观察[J].中国卫生标准管理,2016,7(1):115-116.
[9]阳焕军,周圣明.甘精胰岛素联用伏格列波糖胶囊治疗脆性糖尿病的疗效观察[J].中国处方药,2015,13(4):70-71.
[10]吉永盛.诺和锐+重组甘精胰岛素对24例2型糖尿病患者疗效观察[J].中国实用医药,2017,12(22):125-126.
[11]刘嘉婧.重组甘精胰岛素联合格列美脲治疗糖尿病效果分析[J].北方药学,2016,13(9):55.
[12]李琼,李一梅,谢波,等.阿卡波糖与二甲双胍治疗糖尿病前期疗效的Meta分析[J].中国全科医学,2015,18(3):304-311.
[13]张芳.重组甘精胰岛素联合阿卡波糖治疗老年糖尿病64例临床疗效分析[J].现代实用医学,2016,28(12):1630-1631.
[14]包灵敏,刘存安.甘精胰岛素联合阿卡波糖对2型糖尿病患者血糖达标率及胰岛β细胞功能的影响[J].中国基层医药,2013,20(19):2960-2962.
[15]陈虹燕,何剑英,闵珊,等.重组甘精胰岛素对2型糖尿病患者血糖控制效果的影响[J].北方药学,2016,13(5):111-112.
[2]贾海英,李冬梅.社区门诊新诊断严重高血糖2型糖尿病患者起始基础胰岛素与基础胰岛素联合阿卡波糖治疗的对照研究[J].中国医刊,2018,53(1):41-44.
[3]宋玉香.国产重组甘精胰岛素注射液和来得时治疗糖尿病的安全性对比分析[J].中国实用医药,2016,11(8):150-151.
[4]钱荣立.糖尿病临床指南[M].北京:北京医科大学出版社,2000:210-213.
[5]房彦平,祝小林,李锦,等.阿卡波糖与二甲双胍对我国新发2型糖尿病的疗效及对胰岛功能的影响[J].中国医药科学,2017,7(19):65-67,108.
[6]魏滋鸿,李薇,武卫党,等.新型国产重组甘精胰岛素对1型糖尿病模型大鼠的降糖作用研究[J].药物评价研究,2018,41(8):1446-1449.
[7]樊实真,杨俊朋,张春玲,等.胰岛素促泌剂与阿卡波糖治疗新诊断2型糖尿病的疗效及对胰升血糖素样肽-1的调节作用[J].中国糖尿病杂志,2016,24(4):348-351.
[8]李春花,李可心,张英,等.重组甘精胰岛素联合格列美脲治疗糖尿病疗效观察[J].中国卫生标准管理,2016,7(1):115-116.
[9]阳焕军,周圣明.甘精胰岛素联用伏格列波糖胶囊治疗脆性糖尿病的疗效观察[J].中国处方药,2015,13(4):70-71.
[10]吉永盛.诺和锐+重组甘精胰岛素对24例2型糖尿病患者疗效观察[J].中国实用医药,2017,12(22):125-126.
[11]刘嘉婧.重组甘精胰岛素联合格列美脲治疗糖尿病效果分析[J].北方药学,2016,13(9):55.
[12]李琼,李一梅,谢波,等.阿卡波糖与二甲双胍治疗糖尿病前期疗效的Meta分析[J].中国全科医学,2015,18(3):304-311.
[13]张芳.重组甘精胰岛素联合阿卡波糖治疗老年糖尿病64例临床疗效分析[J].现代实用医学,2016,28(12):1630-1631.
[14]包灵敏,刘存安.甘精胰岛素联合阿卡波糖对2型糖尿病患者血糖达标率及胰岛β细胞功能的影响[J].中国基层医药,2013,20(19):2960-2962.
[15]陈虹燕,何剑英,闵珊,等.重组甘精胰岛素对2型糖尿病患者血糖控制效果的影响[J].北方药学,2016,13(5):111-112.